Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (DE:F6T)
FRANKFURT:F6T
Holding DE:F6T?
Track your performance easily
F6T Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.58 - €7.59
Previous Close€2.94
Volume0.00
Average Volume (3M)256.00
Market Cap
€338.44M
Enterprise Value€151.82M
Total Cash (Recent Filing)$304.88M
Total Debt (Recent Filing)$100.56M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Oct 31, 2024EPS Estimate
-€0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,877,884
10 Day Avg. Volume0
30 Day Avg. Volume256
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.84
Price to Sales (P/S)29.68
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.33
Enterprise Value/Gross Profit2.39
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
€5.33Price Target Upside81.51% Upside
Rating ConsensusHold
Number of Analyst Covering12
Fate Therapeutics News
PremiumCompany Announcements
Fate Therapeutics Strengthens Legal Safeguards for Leadership
PremiumCompany Announcements
Fate Therapeutics Appoints AI Expert to Enhance Board
Bulls Say, Bears Say
Bulls Say
Cash Position And Financial StabilityFate Therapeutics has a strong cash position of $352 million, which is expected to support operations through the end of 2026.
Clinical Trials And SafetyFT522 has shown promising early safety with no significant adverse effects in its initial patient treatments at the 900M dose level.
Financial PerformanceFate Therapeutics achieved collaboration revenue of $6.8 million, exceeding prior forecasts of $5.0 million.
Bears Say
Clinical EfficacyRisks include, but are not limited to: unknown clinical efficacy advantage with FT522 relative to other allogeneic and autologous CAR-T approaches.
Market OpportunitiesA competitive profile with its iPSC derived programs seems far away, and analysts rate FATE Market Perform as they see limited opportunities for value generation in upcoming months.
Strategic FocusThe company announced the decision to halt development of its iPSC-derived CAR-T therapy FT819 in B-cell malignancies (BCM) and instead pursue further development exclusively in autoimmunity.
---
Options Prices
Currently, No data available
---
Ownership Overview
18.52% Insiders
15.87% Mutual Funds
0.03% Other Institutional Investors
52.66% Public Companies and
Individual Investors
F6T FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was €1.57 and its highest was €7.59 in the past 12 months.
What is Fate Therapeutics’s market cap?
Currently, no data Available
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Oct 31, 2024 which is in 12 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Aug 13, 2024. The company reported -€0.301 earnings per share for the quarter, beating the consensus estimate of -€0.424 by €0.122.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -€0.38.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 113,877,884 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -€0.301 in its last earnings report, beating expectations of -€0.424. Following the earnings report the stock price went down -0.297%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Among the largest hedge funds holding Fate Therapeutics’s share is Deerfield Management Company, LP. It holds Fate Therapeutics’s shares valued at 12M.
---
Fate Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€5.33 (81.51% Upside)
€5.33 (81.51% Upside)
Blogger Sentiment
Bullish
DE:F6T Sentiment 100%
Sector Average 71%
Sector Average 71%
Technicals
SMA
Negative
20 days / 200 days
Momentum
59.40%
12-Months-Change
Fundamentals
Return on Equity
-42.10%
Trailing 12-Months
Asset Growth
-9.57%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
---
F6T Earnings Call
Q1 2024
0:00 / 0:00
---
F6T Stock 12 Month Forecast
Average Price Target
€5.33
▲(81.51% Upside)
Technical Analysis
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Cellectis SA
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering F6T
1 Year
1 Year Success Rate
3/13 ratings generated profit
1 Year Average Return
-5.09%
reiterated a buy rating 2 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of -5.09% per trade.
---